An observational study in Digestive System Diseases, Gastrointestinal Neoplasms and Digestive System Neoplasms, sponsored by Nanfang Hospital, Southern Medical University. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-05.
Sponsored by Nanfang Hospital, Southern Medical University · Observational
Among 24 studies in Stomach Neoplasms by Nanfang Hospital, Southern Medical University — 13 open to participants now, 14 under way, 1 of them phase 3. Stomach Neoplasms · Nanfang Hospital, Southern Medical University.
Among the 24 studies in Stomach Neoplasms by Nanfang Hospital, Southern Medical University, this one is the only one that started in 2017, is one of 9 observational ones, and was the 5th registered.
3,399 studies on the registry are indexed under Stomach Neoplasms; 992 are open to participants now.
Browse Stomach Neoplasms studies →13 of the 24 studies in Stomach Neoplasms by Nanfang Hospital, Southern Medical University are open now, in 1 country. Recruiting first, the newest first:
Nanfang Hospital, Southern Medical University · Sites in China
Nanfang Hospital, Southern Medical University · Sites in China
Nanfang Hospital, Southern Medical University · Sites in China
Nanfang Hospital, Southern Medical University · Sites in China
Nanfang Hospital, Southern Medical University · Sites in China
By country, each count listing its studies:
Of the 702 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 3
First in 2012; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 278 across 790 observational studies indexed under Stomach Neoplasms.
Median enrollment 110 across the 15 interventional studies, 155 across the 9 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Nanfang Hospital, Southern Medical University is the lead sponsor of 490 studies on the registry; 214 are open to participants now.
1 of the studies in Stomach Neoplasms by Nanfang Hospital, Southern Medical University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003334Nanfang Hospital, Southern Medical UniversityCorrelation of Psychological Distress and Immune Checkpoint Inhibitors in Gastric Cancer | 2026-12-31 |
Among the 24 studies in Stomach Neoplasms by Nanfang Hospital, Southern Medical University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study proposes to establish a CT radiomics-based prediction model for identifying metastasis of each station lymph nodes in gastric cancer.
This is a prospective, multi-center trial conducted at 4 high-volume gastric cancer centers in China (Nanfang Hospital of Southern Medical University; Sun Yat-Sen University Cancer Center; First Affiliated Hospital, Sun Yat-Sen University; The Third Affiliated Hospital, Sun Yat-Sen University) designed to determine the predicted performance of radiomics-based prediction model for identifying metastasis of each station lymph nodes by enhanced CT for preoperative noninvasive assessment of the lymph node status in patients with gastric cancer. The study includes the construction of CT radiomics-based prediction model and the validation of the prediction model.
3,399 studies on the registry are indexed under Stomach Neoplasms; 992 are open to participants now.
This study's planned enrollment of 500 is above the median of 278 across 790 observational studies indexed under Stomach Neoplasms.
Browse Stomach Neoplasms studies →Nanfang Hospital, Southern Medical University is the lead sponsor of 490 studies on the registry; 214 are open to participants now.
Compared within Stomach Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Digestive System Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
pathologically proven gastric cancer patients who receive preoperative CT and surgical resection in these hospitals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pathological lymph node status of every station
Pathological lymph node status of each station is defined as lymph node metastasis exist or not
Time frame: Pathologic evaluation will be performed for each patient within 1 week after surgery
Survival time
Disease-free survival and overall survival
Time frame: Follow-up from the date of surgery to the date of death.
Lymph node stage (N stage)
Pathological lymph node stage after surgery (N0 stage: no lymph node metastassis; N1 stage: 1-2 lymph node metastasis; N2 stage: 3-6 lymph node metastasis; N3a stage: 7-15 lymph node metastasis;N3b stage: \>15 lymph node metastassis)
Time frame: Pathologic evaluation will be performed for each patient within 1 week after surgery
Started Aug 2017 (actual). Primary completion is estimated for Aug 2018, 12 months after the start.
Of 322 non-industry observational studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 171. This study's planned 12 months is below that.
Counting every sponsor, half of 364 studies reached it within 54 months; a quarter within 29 and three quarters within 119.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanfang Hospital, Southern Medical University →